Aralez Announces Fourth Quarter and Full-Year 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom forecasts quarterly sales below estimates amid rising custom AI chip competition
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
Aralez Pharma (ARLZ) Posts Wider Q4 Loss, Revenues Beat
March 13, 2018 7:02 AM EDTAralez Pharma (NASDAQ: ARLZ) reported Q4 EPS of ($0.68), $0.36 worse than the analyst estimate of ($0.32). Revenue for the quarter came in at $28 million versus the consensus estimate of $25.6 million.
GUIDANCE:
Aralez Pharma sees FY2018 revenue of $140-160 million, versus the consensus of... More
